^
    Back
    Association details:
    Biomarker:BRAF D594G
    Cancer:Cholangiocarcinoma
    Drug:Mekinist (trametinib) (MEK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    JAMA Netw Open
    Title:

    Association of BRAF Variants With Disease Characteristics, Prognosis, and Targeted Therapy Response in Intrahepatic Cholangiocarcinoma

    Published date:
    03/03/2023
    Excerpt:
    He then underwent biopsy and sequencing that revealed a BRAF D594G variant….The patient’s treatment was switched to gemcitabine with oxaliplatin, PD-1, and trametinib, 2 mg/d, orally. This treatment provided marked clinical benefit, and the patient achieved a partial response after 15 weeks.
    Secondary therapy:
    PD1 inhibitor + gemcitabine + oxaliplatin
    DOI:
    10.1001/jamanetworkopen.2023.1476